TriSalus Life Sciences (NASDAQ:TLSI) Research Coverage Started at Oppenheimer

Oppenheimer began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research note released on Monday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $10.00 price target on the stock.

A number of other research firms have also recently issued reports on TLSI. Canaccord Genuity Group restated a buy rating and set a $12.00 price target on shares of TriSalus Life Sciences in a report on Thursday, June 27th. Canaccord Genuity Group began coverage on TriSalus Life Sciences in a report on Thursday, May 30th. They set a buy rating and a $12.00 price target for the company.

TriSalus Life Sciences Stock Down 0.9 %

Shares of TLSI opened at $4.62 on Monday. The firm’s 50 day moving average price is $5.44 and its 200 day moving average price is $7.37. TriSalus Life Sciences has a twelve month low of $3.32 and a twelve month high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The business had revenue of $7.36 million during the quarter.

Insiders Place Their Bets

In other news, CEO Mary T. Szela bought 7,520 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the purchase, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 76.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Wolverine Asset Management LLC acquired a new position in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $240,000. Highbridge Capital Management LLC bought a new stake in TriSalus Life Sciences in the second quarter valued at $1,184,000. Finally, Duquesne Family Office LLC raised its stake in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares in the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.